Cocrystal Ebitda from 2010 to 2025

COCP Stock  USD 1.55  0.02  1.31%   
Cocrystal Pharma EBITDA yearly trend continues to be relatively stable with very little volatility. EBITDA is likely to drop to about -18.3 M. During the period from 2010 to 2025, Cocrystal Pharma EBITDA destribution of quarterly values had range of 107 M from its regression line and mean deviation of  20,238,054. View All Fundamentals
 
EBITDA  
First Reported
2007-09-30
Previous Quarter
-5.4 M
Current Value
-4.9 M
Quarterly Volatility
15.2 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cocrystal Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cocrystal Pharma's main balance sheet or income statement drivers, such as Interest Expense of 1.7 K, Selling General Administrative of 4.1 M or Selling And Marketing Expenses of 8.9 M, as well as many indicators such as Price To Sales Ratio of 383, Dividend Yield of 0.0 or PTB Ratio of 0.69. Cocrystal financial statements analysis is a perfect complement when working with Cocrystal Pharma Valuation or Volatility modules.
  
Check out the analysis of Cocrystal Pharma Correlation against competitors.
To learn how to invest in Cocrystal Stock, please use our How to Invest in Cocrystal Pharma guide.

Latest Cocrystal Pharma's Ebitda Growth Pattern

Below is the plot of the Ebitda of Cocrystal Pharma over the last few years. It is Cocrystal Pharma's EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cocrystal Pharma's overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Pretty Stable
   Ebitda   
       Timeline  

Cocrystal Ebitda Regression Statistics

Arithmetic Mean(22,663,142)
Geometric Mean9,311,482
Coefficient Of Variation(125.74)
Mean Deviation20,238,054
Median(11,743,000)
Standard Deviation28,496,658
Sample Variance812.1T
Range107M
R-Value(0.13)
Mean Square Error854.5T
R-Squared0.02
Significance0.62
Slope(799,945)
Total Sum of Squares12180.9T

Cocrystal Ebitda History

2025-18.3 M
2024-17.4 M
2023-19.4 M
2022-38.4 M
2021-13.8 M
2020-9.3 M
2019-2.2 M

About Cocrystal Pharma Financial Statements

Cocrystal Pharma shareholders use historical fundamental indicators, such as Ebitda, to determine how well the company is positioned to perform in the future. Although Cocrystal Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in Cocrystal Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Cocrystal Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
EBITDA-17.4 M-18.3 M

Additional Tools for Cocrystal Stock Analysis

When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.